Benign Prostatic Hyperplasia (BPH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

GlobalData, October 2011, Pages: 78

Benign Prostatic Hyperplasia (BPH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Benign Prostatic Hyperplasia (BPH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global BPH market. The report identifies the key trends shaping and driving the global BPH market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global BPH sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData’s analysis suggests that the global benign prostatic hyperplasia (BPH) therapeutics market was worth $3.2 billion in 2010. It is forecast to grow at a compound annual growth rate (CAGR) of 6.4% for the next eight years to reach $5.2 billion by 2018. This growth rate is primarily attributed to the recent and impending patent expiry of Uroxatral and Avodart/Avolve in the US and the EU. However, the strong pipeline is set to offset the depleting revenues with the expected launch of Cialis and NX-1207 in the near future. The increase in the elderly population is expected to be a major driver of the BPH therapeutics market.

Scope

The report provides information on the key drivers and challenges of the BPH market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) BPH market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as phosphodiesterase-5 (PDE5) inhibitors, apoptosis inducers, estrogen receptor agonist and vasopressin agonist.
- Analysis of the current and future competition in the seven key countries BPH market. Key market players covered are Eli Lilly and Company, and Nymox Pharmaceutical.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the BPH therapeutics market.
- Analysis of key recent licensing and partnership agreements in BPH market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global BPH market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global BPH market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global BPH market landscape? – Identify, understand and capitalize.

Keywords

Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials

1
1

1.1 List of Tables
1.2 List of Figures
2 Benign Prostatic Hyperplasia (BPH): Introduction
2.1 Disease Overview
2.2 Epidemiology
2.3 Pathophysiology
2.4 Symptoms
2.5 Diagnosis
2.6 Treatment
2.6.1 Alpha Blockers
2.6.2 5-Alpha Reductase Inhibitors
2.6.3 Combination Therapy
2.6.4 Anticholinergics
2.6.5 Surgery
2.7 GlobalData Pipeline Report Guidance
3 Benign Prostatic Hyperplasia Therapeutics: Market Characterization
3.1 Benign Prostatic Hyperplasia Therapeutics Market Size (2005-2010) – Global
3.2 Benign Prostatic Hyperplasia Therapeutics Market Forecast (2010-2018) – Global
3.3 Benign Prostatic Hyperplasia Therapeutics Market Size (2005-2010) – The US
3.4 Benign Prostatic Hyperplasia Therapeutics Market Forecast (2010-2018) – The US
3.5 Benign Prostatic Hyperplasia Therapeutics Market Size (2005-2010) – The UK
3.6 Benign Prostatic Hyperplasia Therapeutics Market Forecast (2010-2018) – The UK
3.7 Benign Prostatic Hyperplasia Therapeutics Market Size (2005-2010) – France
3.8 Benign Prostatic Hyperplasia Therapeutics Market Forecast (2010-2018) – France
3.9 Benign Prostatic Hyperplasia Therapeutics Market Size (2005-2010) – Germany
3.10 Benign Prostatic Hyperplasia Therapeutics Market Forecast (2010-2018) – Germany
3.11 Benign Prostatic Hyperplasia Therapeutics Market Size (2005-2010) – Italy
3.12 Benign Prostatic Hyperplasia Therapeutics Market Forecast (2010-2018) – Italy
3.13 Benign Prostatic Hyperplasia Therapeutics Market Size (2005-2010) – Spain
3.14 Benign Prostatic Hyperplasia Therapeutics Market Forecast (2010-2018) – Spain
3.15 Benign Prostatic Hyperplasia Therapeutics Market Size (2005-2010) – Japan
3.16 Benign Prostatic Hyperplasia Therapeutics Market Forecast (2010-2018) – Japan
3.17 Drivers and Barriers for the Benign Prostatic Hyperplasia Therapeutics Market
3.17.1 Drivers for the Benign Prostatic Hyperplasia Therapeutics Market
3.17.2 Barrier for the Benign Prostatic Hyperplasia Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway
4 Benign Prostatic Hyperplasia Therapeutics: Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the Benign Prostatic Hyperplasia Therapeutics Market
4.3.1 Duodart (fixed dose combination of Avodart (dutasteride) and tamsulosin)
4.3.2 Alfuzosin (Xatral/ Uroxatral)
4.3.3 Tamsulosin (Flomax, Harnal)
4.3.4 Terazosin (Hytrin)
4.3.5 Finasteride (Proscar)
4.3.6 Doxazosin (Cardura, Cardura XL)
4.3.7 Avodart/Avolve (Dutasteride)
4.3.8 Silodosin (Rapaflo / Urief)
4.4 Key Takeaway
5 Benign Prostatic Hyperplasia Therapeutics: Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.2.1 Benign Prostatic Hyperplasia Therapeutics – Pipeline by Phases of Development
5.2.2 Benign Prostatic Hyperplasia Therapeutics – Pre-Registration Pipeline
5.2.3 Benign Prostatic Hyperplasia Therapeutics – Phase III Pipeline
5.2.4 Benign Prostatic Hyperplasia Therapeutics – Phase II Pipeline
5.2.5 Benign Prostatic Hyperplasia Therapeutics – Phase I Pipeline
5.2.6 Benign Prostatic Hyperplasia Therapeutics – Preclinical Pipeline
5.2.7 Technology Trends Analytical Framework
5.2.8 Technology Trend Analytical Framework Description
5.3 Benign Prostatic Hyperplasia Therapeutics – Clinical Pipeline by Mechanism of Action
5.4 Benign Prostatic Hyperplasia Therapeutics – Promising Drugs with Novel Mechanisms of Action under Clinical Development
5.5 Profiles of Promising Drugs under Clinical Development
5.5.1 Cialis (tadalafil)
5.5.2 NX-1207
5.6 Key Takeaway
6 Benign Prostatic Hyperplasia Therapeutics: Clinical Trials Mapping
6.1 Clinical Trials by Country
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Prominent Sponsors
6.6 Top Companies Participating in Therapeutics Clinical Trials
7 Benign Prostatic Hyperplasia Therapeutics: Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Implications for Future Market Competition
8 Benign Prostatic Hyperplasia Therapeutics: Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Eli Lilly and Company
8.2.2 Nymox Pharmaceutical Corporation
9 Benign Prostatic Hyperplasia(MM) Therapeutics: Licensing and Partnership Deals
10 Benign Prostatic Hyperplasia Therapeutics: Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Benign Prostatic Hyperplasia (BPH), Prevalence, Seven Major Markets, 2010
Table 2: Benign Prostatic Hyperplasia Therapeutics Market, Global, Revenue ($bn), 2005–2010
Table 3: Benign Prostatic Hyperplasia Therapeutics Market, Global, Forecast ($bn), 2010–2018
Table 4: Benign Prostatic Hyperplasia Therapeutics Market, The US, Revenue ($bn), 2005–2010
Table 5: Benign Prostatic Hyperplasia Therapeutics Market, The US, Revenue ($bn), 2010–2018
Table 6: Benign Prostatic Hyperplasia Therapeutics Market, The UK, Revenue ($m), 2005–2010
Table 7: Benign Prostatic Hyperplasia Therapeutics Market, The UK, Forecast ($m), 2010–2018
Table 8: Benign Prostatic Hyperplasia Therapeutics Market, France, Revenue ($m), 2005–2010
Table 9: Benign Prostatic Hyperplasia Therapeutics Market, France, Forecast ($m), 2010–2018
Table 10: Benign Prostatic Hyperplasia Therapeutics Market, Germany, Revenue ($m), 2005–2010
Table 11: Benign Prostatic Hyperplasia Therapeutics Market, Germany, Forecast ($m), 2010–2018
Table 12: Benign Prostatic Hyperplasia Therapeutics Market, Italy, Revenue ($m), 2005–2010
Table 13: Benign Prostatic Hyperplasia Therapeutics Market, Italy, Forecast ($m), 2010–2018
Table 14: Benign Prostatic Hyperplasia Therapeutics Market, Spain, Revenue ($m), 2005–2010
Table 15: Benign Prostatic Hyperplasia Therapeutics Market, Spain, Forecast ($m), 2010–2018
Table 16: Benign Prostatic Hyperplasia Therapeutics Market, Japan, Revenue ($m), 2005–2010
Table 17: Benign Prostatic Hyperplasia Therapeutics Market, Japan, Forecast ($m), 2010–2018
Table 18: Benign Prostatic Hyperplasia Therapeutics – Pre-Registration Pipeline
Table 19: Benign Prostatic Hyperplasia Therapeutics – Phase III Pipeline
Table 20: Benign Prostatic Hyperplasia Therapeutics – Phase II Pipeline
Table 21: Benign Prostatic Hyperplasia Therapeutics – Phase I Pipeline
Table 22: Benign Prostatic Hyperplasia Therapeutics – Preclinical Pipeline
Table 23: Benign Prostatic Hyperplasia Therapeutics – Promising Drugs Under Clinical development, 2011
Table 24: Benign Prostatic Hyperplasia Therapeutics – Clinical Trials by Country, 2011
Table 25: Benign Prostatic Hyperplasia Therapeutics – Clinical Trials by Phase, 2011
Table 26: Benign Prostatic Hyperplasia Therapeutics – Clinical Trials by Status, 2011
Table 27: Benign Prostatic Hyperplasia Therapeutics – Clinical Trials by Overall Sponsors, 2011
Table 28: Benign Prostatic Hyperplasia Therapeutics – Clinical Trials by Prominent Sponsors, 2011
Table 29: Eli Lilly and Company – Genitourinary Pipeline, 2011
Table 30: Nymox Pharmaceutical Corporation – Genitourinary Pipeline, 2010
Table 31: Benign Prostatic HyperplasiaTherapeutics, Global, Deals, 2011

1.2 List of Figures
Figure 1: Benign Prostatic Hyperplasia (BPH)
Figure 2: Benign Prostatic Hyperplasia Therapeutics Market, Global, Revenue ($bn), 2005–2010
Figure 3: Benign Prostatic Hyperplasia Therapeutics, Market Share ($m), 2010
Figure 4: Benign Prostatic Hyperplasia Therapeutics Market, Global, Forecast ($bn), 2010–2018
Figure 5: Benign Prostatic Hyperplasia Therapeutics, Market Share ($m), 2018
Figure 6: Benign Prostatic Hyperplasia Therapeutics Market, The US, Revenue ($bn), 2005–2010
Figure 7: Benign Prostatic Hyperplasia Therapeutics Market, The US, Forecast ($bn), 2010–2018
Figure 8: Benign Prostatic Hyperplasia Therapeutics Market, The UK, Revenue ($m), 2005–2010
Figure 9: Benign Prostatic Hyperplasia Therapeutics Market, The UK, Forecast ($m), 2010–2018
Figure 10: Benign Prostatic Hyperplasia Therapeutics Market, France, Revenue ($m), 2005–2010
Figure 11: Benign Prostatic Hyperplasia Therapeutics Market, France, Forecast ($m), 2010–2018
Figure 12: Benign Prostatic Hyperplasia Therapeutics Market, Germany, Revenue ($m), 2005–2010
Figure 13: Benign Prostatic Hyperplasia Therapeutics Market, Germany, Forecast ($m), 2010–2018
Figure 14: Benign Prostatic Hyperplasia Therapeutics Market, Italy, Revenue ($m), 2005–2010
Figure 15: Benign Prostatic Hyperplasia Therapeutics Market, Italy, Forecast ($m), 2010–2018
Figure 16: Benign Prostatic Hyperplasia Therapeutics Market, Spain, Revenue ($m), 2005–2010
Figure 17: Benign Prostatic HyperplasiaTherapeutics Market, Spain, Forecast ($m), 2010–2018
Figure 18: Benign Prostatic Hyperplasia Therapeutics Market, Japan, Revenue ($m), 2005–2010
Figure 19: Benign Prostatic Hyperplasia Therapeutics Market, Japan, Forecast ($m), 2010–2018
Figure 20: Opportunity and Unmet Need in the BPH Therapeutics Market, 2011
Figure 21: Strategic Competitor Assessment of the Marketed Products for BPH Therapeutics,2011
Figure 22: Benign Prostatic Hyperplasia Therapeutics Pipeline by Phase of Clinical Development, 2011
Figure 23: Technology Trends Analytic Framework of the BPH Therapeutics Pipeline, 2011
Figure 24: Technology Trends Analytic Framework of the BPH Therapeutics Pipeline – Description, 2010
Figure 25: Benign Prostatic Hyperplasia Therapeutics – Pipeline by Mechanism of Action, 2011
Figure 26: Benign Prostatic Hyperplasia Therapeutics – Clinical Trials by Country, 2011
Figure 27: Benign Prostatic Hyperplasia Therapeutics – Clinical Trials by Phase, 2011
Figure 28: Benign Prostatic Hyperplasia Therapeutics – Clinical Trials by Status, 2011
Figure 29: Benign Prostatic Hyperplasia Therapeutics – Clinical Trials by Overall Sponsors, 2011
Figure 30: Benign Prostatic Hyperplasia Therapeutics – Clinical Trials by Prominent Sponsors, 2011
Figure 31: Benign Prostatic Hyperplasia – Clinical Trials by Top Sponsors, 2011
Figure 32: Benign Prostatic Hyperplasia Therapeutics Market, Drivers and Barriers, 2011
Figure 33: Implications for Future Market Competition in Benign Prostatic Hyperplasia Therapeutic Market, 2011
Figure 34: Benign Prostatic Hyperplasia Therapeutics – Pipeline by Company, 2011
Figure 35: GlobalData Market Forecasting Model

GlobalData, the industry analysis specialist, has released its new report, “Benign Prostatic Hyperplasia (BPH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global BPH market. The report identifies the key trends shaping and driving the global BPH market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global BPH sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The Benign Prostatic Hyperplasia Therapeutics Market is Forecast to Show Modest Growth Until 2018

GlobalData’s analysis suggests that the global benign prostatic hyperplasia (BPH) therapeutics market was worth $3.2 billion in 2010. It is forecast to grow at a compound annual growth rate (CAGR) of 6.4% for the next eight years to reach $5.2 billion by 2018. This growth rate is primarily attributed to the recent and impending patent expiry of Uroxatral and Avodart/Avolve in the US and the EU. However, the strong pipeline is set to offset the depleting revenues with the expected launch of Cialis and NX-1207 in the near future. The increase in the elderly population is expected to be a major driver of the BPH therapeutics market.

BPH Therapeutics Market, Global, Revenues and Market Forecast ($bn), 2005–2018

Sources: Parsons JK, Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors, Curr Bladder Dysfunct Rep. 2010; 5(4):212-218; McVar KT, BPH: Epidemiology and Comorbidities, Am J Manag Care. 2006; 12(5 Suppl):S122-8; GlobalData; GlobalData Epidemiology-based Market Forecasting Model; Primary Research Interviews; KOL Interviews

Eli Lilly and Company
Nymox Pharmaceutical Corporation

Customers who bought this item also bought

• Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms (Event Driven)
• Epidemiology: Benign Prostatic Hyperplasia - Expected to continue growing as the male population ages
• Urological Disorders Therapeutics to 2017 - Large Number of Licensing Deals for Approved Products Reflects a Pessimistic R&D Future
• DRG Insights: Benign Prostate Hyperplasia (G7)
• Men's Health Therapeutics Market to 2017 - Availability of Generic Sildenafil from 2012 to Restrain Market Growth
• Minimally Invasive BPH and Prostate Cancer Treatment Devices Markets Worldwide
• Nephrology and Urology Devices Market – Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018
• Medical Laser Systems - Global Strategic Business Report
• Medical Nutrition - A Global Market Overview
• Diabetes Diagnostics - Global Strategic Business Report